MLYS — Mineralys Therapeutics Share News
0.000.00%
Last trade - 00:00Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway
Mineralys Therapeutics falls after $150 mln stock deal
Brief: Mineralys Therapeutics Announces Pricing Of $150 Million Underwritten Offering Of Common Stock
Brief: Mineralys Therapeutics Announces Repurchase Of Royalty Obligations In Tanabe License Agreement And Concurrent Financing
Brief: Mineralys Therapeutics Presents New Data From The Phase 3 Launch-Htn Trial Of Lorundrostat
Mineralys' pill cuts blood pressure in kidney disease patients
Brief: Mineralys Therapeutics Announces Presentation Of New Data From The Late-Stage Launch-Htn Trial Of Lorundrostat
AstraZeneca's blood pressure drug wins U.S. approval
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Immunic rises after board hire of MS drug veteran
Brief: Mineralys Therapeutics Appoints Jeffrey A. Munsie As Chief Legal Officer
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Mineralys Therapeutics Q4 net loss narrows as R&D falls
Brief: Mineralys Therapeutics Q4 EPS USD -0.4
Brief: Mineralys Therapeutics Announces FDA Acceptance Of NDA For Lorundrostat For Treatment Of Adults With Hypertension And Topline Explore-Osa Trial Results
Brief: Mineralys Therapeutics Filed NDA For Lorundrostat To U.S. FDA In Late 2025